Analiese E Mason Jude MD
MessageRoles available for:
-
Fractional
-
Consulting
-
Contract
-
Interim
-
Vancouver, British Columbia, Canada
Analiese E Mason Jude MD
Add to favorites
Roles available for:
-
Fractional
-
Consulting
-
Contract
-
Interim
-
Vancouver, British Columbia, Canada
Experience
Fractional role
Strengths in this role: Presenting complex materials to varied audiences Critical thinking problem-solving Data analysis Advisory board planning Speaker training Attending conferences Cross functional collaboration Communication Scientific communication Patient advocacy Medical Legal Regulatory compliance Working well under pressure Sales training Curriculum development Screening for talent acquisition Licensing and white label strategies Training AI models in medicine and
Industry Group: Health
Industry: Biotechnology
Years of experience: 25 years
Company name: iMpaviD Life Sciences Consulting
Company size: 2 employees
Role in this company: Principal Consultant | Fractional Chief Medical Officer | Director Medical Affairs | iMpaviD Life Sciences Consulting 2012–2025 • Direct strategy and analytics for multiple life sciences companies from early startups to the global pharmaceutical brands Generative. AI training modeling consultancy in STEM and Medicine for DataAnnotation | Outlier | Open Innovation Counsel OIC
Company name: Mood Mentor | Bipolar Buddy
Company size: 6 employees
Role in this company: • Chief Medical Officer (interim) Principal Investigator: Oversaw development of Bipolar Buddy | Mood Mentor app including pilot study design, user engagement analytics, and validation strategy in collaboration with University of Edinburgh and the NHS. 2021-2024
Company name: NanoVec
Company size: 100 employees
Role in this company: Medical Advisor | NanoVec North America | 2019–2021 • Supported commercialization strategy for nanodermaceutical product line; negotiated licensing with global CPG brands Unilever and L'Oréal.
Company name: New Concept Pharmaceuticals
Company size: 4 employees
Role in this company: Chief Medical Officer (Interim) | New Concept Pharmaceuticals | 2019 • Evaluated clinical-stage assets for viability; led cross-border regulatory planning and VC engagement.
Company name: Sun Pharmaceutical Inc
Company size: 45,000 employees
Role in this company: Medical Science Liaison Oncology & Dermatology | Sun Pharma Canada | 2019–2025 • Led provincial launch efforts for ILUMYA™psoriasis and ODOMZO®, Gorlin Syndrome securing early adoption through strategic KOL partnerships | BC Cancer Agency • Developed MLR-approved materials, including national scientific slide decks, later adopted by US operations for sonidegib for rare skin disease NBCCS • Facilitated IITs and early access protocols, driving patient-centered clinical development.
